טוען...
Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms after Randomized Single-Therapy Treatment
OBJECTIVES: To compare 12 week outcomes of single-therapy tolterodine (Detrol LA (®)) extended release to intravaginal estrogen (Estrace (®)) for overactive bladder (OAB) symptoms and characterize 24 and 52 week outcomes in women undergoing combined therapy. METHODS: A single-site randomized, open-l...
שמור ב:
| הוצא לאור ב: | Female Pelvic Med Reconstr Surg |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4919279/ https://ncbi.nlm.nih.gov/pubmed/26945271 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/SPV.0000000000000256 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|